Last edition
News about "Atopic Dermatitis (AD)"
Sanofi to not Submit Amlitelimab in Atopic Dermatitis for Global Regulatory Reviews
Sanofi will not seek global regulatory approval for amlitelimab in Atopic Dermatitis (AD) after efficacy and safety data did not support further development.
Atopic Dermatitis (AD) | 27/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members